- Home
- BROG vs IKT Comparison
BROG vs IKT Comparison
Compare BROG & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BROG
- IKT
- Stock Information
- Founded
- BROG 2019
- IKT 2008
- Country
- BROG United Arab Emirates
- IKT United States
- Employees
- BROG N/A
- IKT N/A
- Industry
- BROG Integrated oil Companies
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- BROG Energy
- IKT Health Care
- Exchange
- BROG Nasdaq
- IKT Nasdaq
- Market Cap
- BROG 137.5M
- IKT 159.2M
- IPO Year
- BROG N/A
- IKT 2020
- Fundamental
- Price
- BROG $1.29
- IKT $2.81
- Analyst Decision
- BROG
- IKT Strong Buy
- Analyst Count
- BROG 0
- IKT 2
- Target Price
- BROG N/A
- IKT $6.50
- AVG Volume (30 Days)
- BROG 56.3K
- IKT 288.1K
- Earning Date
- BROG 02-15-2025
- IKT 11-14-2024
- Dividend Yield
- BROG N/A
- IKT N/A
- EPS Growth
- BROG N/A
- IKT N/A
- EPS
- BROG N/A
- IKT N/A
- Revenue
- BROG $73,020,415.00
- IKT $1.00
- Revenue This Year
- BROG N/A
- IKT N/A
- Revenue Next Year
- BROG N/A
- IKT N/A
- P/E Ratio
- BROG N/A
- IKT N/A
- Revenue Growth
- BROG N/A
- IKT N/A
- 52 Week Low
- BROG $0.80
- IKT $1.12
- 52 Week High
- BROG $6.66
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- BROG 46.04
- IKT 45.17
- Support Level
- BROG $1.21
- IKT $2.55
- Resistance Level
- BROG $1.46
- IKT $2.90
- Average True Range (ATR)
- BROG 0.16
- IKT 0.29
- MACD
- BROG -0.01
- IKT -0.07
- Stochastic Oscillator
- BROG 35.42
- IKT 27.66
About BROG Brooge Energy Limited
Brooge Energy Ltd is an Oil Refinery & Storage Company in the United Arab Emirates. The company generates revenue from the leasing of storage capacity of tanks and other ancillary services.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.